What are LHRH agonists and antagonists in prostate cancer?
LHRH (also called GnRH) drugs control testosterone by turning down the signals from the brain to the testes. In advanced or metastatic prostate cancer, they are used to achieve “androgen deprivation therapy” (ADT). An LHRH agonist initially causes a temporary rise in LH/testosterone (“flare”) before lowering testosterone to castrate levels. An LHRH antagonist does not cause this initial flare and lowers testosterone more directly.
How do LHRH agonists work, and what is “flare”?
With LHRH agonists, the pituitary initially responds to the drug, which can raise LH and testosterone for a short period. That flare can worsen symptoms in men with bulky or symptomatic metastatic disease (for example, bone pain) early in treatment. Because of that risk, clinicians often use additional medications to block flare when starting an agonist.
After the initial stimulation, continuous exposure downregulates LHRH receptors, and testosterone levels fall to castrate range.
How do LHRH antagonists differ from agonists?
LHRH antagonists bind to LHRH receptors in a way that rapidly suppresses LH/testosterone production. They generally avoid the testosterone “flare” seen with agonists, so they can be preferred when flare risk is a major concern, such as in men with symptomatic metastases early in ADT.
Which ADT approach is used for prostate cancer?
Doctors choose between agonists and antagonists based on clinical factors like symptom burden, urgency of testosterone suppression, and treatment logistics (injectable schedule and patient preferences). Both drug types aim for the same therapeutic goal: sustained castrate-level testosterone.
What side effects do these therapies have in common?
Because both approaches reduce testosterone, they share many ADT-related effects, which can include hot flashes, sexual dysfunction, fatigue, weight gain, and mood changes. Lower testosterone can also contribute to bone thinning (osteoporosis) and increased cardiovascular/metabolic risk.
When might a clinician choose an antagonist over an agonist?
A common reason is flare risk. If a patient has painful or threatening metastatic disease at the start of ADT, an antagonist’s lack of flare can be clinically useful. The choice can also depend on local availability and the specific dosing schedule of each medication.
Are these drugs used only for metastatic prostate cancer?
They can be used in multiple settings where ADT is indicated, including locally advanced or high-risk disease, depending on the treatment plan. The core principle remains the same: suppress testosterone to slow cancer growth that depends on androgens.
How fast does testosterone fall?
Antagonists generally lower testosterone quickly without flare. Agonists lower testosterone after the initial rise; the exact timeline depends on the specific agent and dosing schedule. The key clinical distinction is that antagonists avoid early testosterone surges that can worsen symptoms.
What happens if treatment is stopped or interrupted?
If ADT is stopped, testosterone can recover and the cancer may become more responsive to androgens again. Many treatment plans use scheduled ongoing therapy unless otherwise directed by the oncology team.
Patient questions people commonly ask
Patients often ask whether they will feel worse right after starting therapy (flare concern, mainly with agonists), how quickly symptoms may improve, and what to do about bone pain or urinary obstruction during the first days. The choice of agent can affect early symptom risk.
Sources
No source links were provided with the question, so no citations are included. If you share the specific LHRH agonist/antagonist drugs you mean (or a guideline/article you’re using), I can tailor the answer to those agents and their exact dosing and flare-management recommendations.